Dennis Curran is the Director of Product Management for BIOVIA and is focused on the integration of BIOVIA Software into customer solutions for scientific research. His direct product responsibilities include the BIOVIA Workbook and BIOVIA Laboratory Operations Suite. Since receiving his degree in Analytical Chemistry from Tufts University in 1985, Mr. Curran has been involved in the laboratory automation and software industries. His 30 years of career experience spans the scientific, engineering, software and management aspects of projects in the life sciences industry, from Drug Discovery through Development and Quality Control operations.
1. What are you looking forward to discussing with the audience?
So many pharmaceutical and biopharmaceutical organizations are increasing their focus on biotherapeutic drug development in order to remain competitive in the market. Unfortunately, this can backfire when these organizations don’t take in to account the resources required for managing the additional complex data and processes involved. This can increase exposure to compliance risk, decrease overall productivity and extend the time to market for new products. I’m excited to have the opportunity to show the audience that there is a better way to not only manage, but leverage biologics data by eliminating inefficient paper-based workflows, reducing the effort for creating experiments, providing better understanding of processes and products, and much more.
2. You’ve mentioned that the biologics R&D workflow is similar to small molecule R&D at the highest level but that there are differences in the details. Can you explain what changes as an organization shifts toward biotherapeutic development?
In short, biologic development demands unique processes due to the added complexity of biological systems. Compared to small molecule R&D, biologics workflows generate a large amount and a large variety of complex data. However, being able to distill the information and track the genealogy of how to get to an end entity is critical. This requires some advanced data and workflow management.
3. Why do you feel this topic is important?
In a recent market survey we conducted, we asked responders what percentage of their biopharmaceutical development processes are being supported with manual methods like pen/paper and/or Excel spreadsheets. To our surprise (and concern), we found that almost half of the responses indicated that at least 75% of their biologic development processes were supported by manual methods. The industry clearly needs to see that an electronic solution is available and can manage the end-to-end biologics workflow without the risk or hindrance of manual work.
4. What do you hope the audience will learn from this webinar?
By attending this webinar, I hope the audience will see the true potential impact of transitioning from a paper-based to an electronic Biologics solution covering all activities of the development process end to end and how that positively affects their bottom line.
Dennis will be presenting BIOVIA’s webinar ‘Building Better Biologics, Faster‘ on the 22nd July. Register here.